FYARRO ® sales of $6.2 million for Q2 2024, a 15% quarter over quarter sales growth Interim analysis of two-thirds of fully enrolled PRECISION1 trial planned for Q3 2024 Conference call to be held today at 8:30 am EDT LOS ANGELES , Aug. 7, 2024 /PRNewswire/ -- Aadi Bioscience, Inc.
(NASDAQ: AADI ), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the second quarter ended June 30, 2024 , and highlighted recent corporate progress. "The second quarter saw quarter over quarter sales growth for FYARRO, as anticipated, and an increase in demand across both new and existing accounts, including from major oncology centers. Approximately 80 percent of accounts have ordered multiple times already this year, reflecting the clinical value of FYARRO for patients with advanced malignant PEComa," said Dave Lennon , President and CEO of Aadi Bioscience.
"Looking ahead, we will provide the next interim update from PRECISION1, a tumor-agnostic study that enrolled any tumor type presenting with qualifying TSC1 or TSC2 inactivating alterations, later in the third quarter. With this study, nab -sirolimus has the potential to demonstrate a meaningful impact on the lives of patients who have already received standard therapies appropriate for their tumor type and stage of disease." Recent Operational Highlights FYARRO net product sales were $6.
2 million in the s.